Taken together, our scRNA‐seq analysis showed that the IDH‐SG and IDH‐NO tumors exhibited distinct features both on the tumor cell and immune cell levels, suggesting that patient stratification based on IDH mutation subgroup status may be clinically meaningful, indicating distinct therapeutic strategies in the future. This evidence concerns the gene IDH2 and neoplasm.